Stasenko M, et al. - Researchers analyzed patients with BRCA-associated ovarian cancer [including epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC)] with brain metastases (BM), to determine the clinical outcomes of these patients. BM was present in 91 (2.5%) of 3649 patients with EOC. For 63 (69%) cases, germline mutation status was available; a BRCA1/2 mutation was present in 21 (35%) of these (15 BRCA1, 6 BRCA2). The groups had similar clinical features. The likelihood of having isolated BM was more in BRCA-mutated (mBRCA) patients, which could represent a factor in their long survival. The pursuit of aggressive therapy for mBRCA EOC patients with BM is thus supported. The outcomes in patients with EOC and BM were compared by mutation status, on the largest level to date in this present investigation.